Children's Hospital of Philadelphia study highlights the role of genetic and developmental pathways on fetal health and outcomes in congenital heart disease PHILADELPHIA, Nov. 3, 2025 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) discovered that placental malperfusion (PMP), a condition that disrupts blood flow in the placenta, is common in fetuses with congenital heart disease (CHD) and is linked to poor fetal growth, longer hospital stays and potentially increase

Acquisition strengthens Endeavor's leadership in neurosciences, expands access to nationally recognized headache and migraine care EVANSTON, Ill., Nov. 3, 2025 /PRNewswire/ -- Endeavor Health℠ today announced that it has acquired Diamond Headache Clinic to form the Endeavor Health Diamond Headache & Migraine Center. Diamond is a practice with more than 40 years of experience providing cutting-edge headache and migraine treatment to patients in Chicago, the Midwest and throughout the U.S. The a

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that Didric Cederholm has joined its Board of Directors, chaired by Oran M

One day after stepping down as CDER Director, George Tidmarsh has said he will fight the investigations into his conduct and is reconsidering his decision. Tidmarsh’s intentions were shared with a handful of senior FDA staff in the Office of New Drugs (OND) during a meeting of supervisors on Monday, which was held virtually. At the meeting, OND Director Mary Thanh Hai relayed Tidmarsh’s comments to staff that he was on administrative leave and that he’s not resigning, according to a person famil

SARASOTA, Fla., Nov. 3, 2025 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will participate in a panel discussion at the BioFlorida "Florida Innovation Conference" being held November 5-7, 2025, at the JW Marriot

Two federal district courts have reached opposite conclusions in cases challenging states’ authority to regulate how drugmakers distribute 340B discounts. An Oklahoma federal judge on Friday preliminarily blocked the state from forcing AbbVie, Novartis and AstraZeneca to comply with certain provisions of a recently enacted law that requires drugmakers to deliver 340B-discounted drugs to an unlimited number of contract pharmacies. The same day, a federal judge in Colorado rejected AbbVie’s attemp

Biohope signs a know-how agreement with Mayo Clinic to advance development and commercialization of its personalized transplant diagnostic device. We are thrilled to collaborate with Mayo Clinic, to utilize their expertise in transplant medicine” — Isabel Portero, Biohope's CEO MADRID, MADRID, SPAIN, November 3, 2025 / EINPresswire.com / -- Biohope, a Spanish company specialized in personalized medicine solutions for transplant and autoimmune patients, has signed a know-how agreement with Mayo C

NEWNAN, Ga., Nov. 3, 2025 /PRNewswire/ -- United Vein & Vascular Centers (UVVC), a national leader in minimally invasive vein and vascular care, is proud to announce the official opening of its newest clinic in Newnan, Georgia. Beginning today, patients can visit the new facility located at 354 Newnan Crossing Bypass, Suite 210, Newnan, GA 30263, for expert, outpatient vein and vascular treatment. The Newnan clinic expands UVVC's growing network of state-of-the-art centers across the country, pr

Almost half of patients medication free at 12 months. Vast majority of patients achieved significant IOP reduction on the same or fewer medications. Strong 12-month safety and efficacy results: no serious adverse events. REDWOOD CITY, Calif., Nov. 3, 2025 /PRNewswire/ -- Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical data on VisiPlate® Aqueous Shunt from the VITA Trial during the 2025 Amer

Decision brings total number of Medicaid programs offering WGS coverage to 30 states and Puerto RicoHOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading clinical diagnostic laboratory at the forefront of genetic testing, today announced its support for Medi-Cal's (California’s Medicaid) decision to begin covering whole genome sequencing (WGS) as of November 1, 2025. This landmark coverage expands access to WGS for patients across the state of California and brings the total nu